◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound WATCH-LIST HIGH

SM-04554

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict WATCH-LIST HIGH

"Mechanistically interesting — a Wnt activator is a credible new lever for AGA, distinct from the existing minoxidil + 5αRI canon, and Phase 2 produced a real (if modest) signal at the 0.15% concentration with the unexpected pattern of *continued* gains during washout. But (a) Phase 3 results have never been publicly disclosed and Biosplice removed the asset from active pipeline, the strongest possible negative read in commercial pharma, (b) the inverted dose-response (0.15% > 0.25%) was concerning and never explained, (c) the sister Wnt-pathway program lorecivivint (SM04690) for knee OA also failed Phase 3 — platform-credibility hit, (d) for users in this archetype: no MPB at 20 with intact HPG axis, so there is no substrate for any AGA drug (same logic as minoxidil/finasteride for this user). Watch-list because the mechanism is interesting and a successful re-licensee or successor compound (PP-405 in particular is a different angle on the \"wake stem cells\" thesis) would be relevant if MPB ever appears, but as currently constituted SM-04554 is a failed trial drug with no commercial path. Do not self-trial — research-chem topical applied at random vehicle concentration is dosing for nothing."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload, no MPB (this-archetype)
    WATCH-LIST

    → effectively SKIP-FOR-NOW. No MPB at 20 with intact HPG axis, so no AGA substrate exists. This drug is treatment, not prevention. Even with MPB, SM-04554 is a failed-trial drug with no commercial path — not a sensible choice over the proven minoxidil + finasteride canon.

  • 20-30 with early MPB, treatment-naive
    SKIP

    for SM-04554 specifically; STRONG for the standard AGA canon (topical minoxidil + finasteride + ketoconazole). Revisit Wnt-activator class only if PP-405 (a different mechanism in the same "wake stem cells" thesis) gets a Phase 3 efficacy hit.

  • 20-30 with aggressive MPB or non-response to topical
    SKIP

    for SM-04554; consider RU58841 add-on, dutasteride, or LDOM instead — all of these have community-evidence bases SM-04554 lacks.

  • 30-50, executive maintenance, established MPB
    SKIP

    Same logic — better-evidenced drugs are available with simpler sourcing.

  • 50+, advanced MPB
    SKIP

    Late-stage exhausted follicles are hard for any drug to recover; the Wnt-stem-cell thesis doesn't address the underlying miniaturization in the way 5αRIs + transplant do.

  • Anxiety-prone
    NEUTRAL

    Topical, minimal systemic exposure — no anxiety implications.

  • High athletic load, untested status
    NEUTRAL

    Not WADA-listed; topical with minimal systemic exposure. No performance impact.

  • Sleep-disordered
    NEUTRAL
  • Recovery-focused (post-injury, post-illness)
    NEUTRAL

    No relevant interaction with healing or recovery.

  • Strength/anabolic-focused, on TRT/AAS with MPB
    SKIP

    TRT/AAS-driven AGA is best addressed with topical/oral minoxidil ± topical AR antagonist (RU58841 / clascoterone) ± oral 5αRI (debated on TRT). SM-04554 has no role here.

▸ Subjective experience (deep)

Topical, no psychoactive effect, no acute physiological feeling.

What we know from trials:

  • Mild local tolerability — minor scalp redness/irritation possible from the vehicle, low-frequency in trial reports
  • One eye irritation event in Phase 1 at 0.45% (highest dose tested, never carried forward)
  • No systemic effects, no cardiovascular signal, no sexual side effect signal — fundamentally different risk profile from oral 5αRIs
  • Like most AGA topicals, no felt benefit — any effect manifests over weeks via macrophotography or trichoscopy

Important caveat: if you sourced research-chem powder and made your own topical, you would not be reproducing the Samumed clinical formulation — vehicle composition affects penetration, stability, and bioactivity; this is not a "DIY-equivalent" molecule like simple minoxidil sulfate that has been characterized in many vehicles.

▸ Tolerance + cycling deep dive
  • Tolerance: Unknown. The "wake stem cells, then withdraw" thesis predicts no tolerance — the drug pushes a one-time cell-state transition rather than tonic receptor activation. Phase 2 day-90-to-day-135 continued gain pattern is consistent with this; whether it holds out to 6/12/24 months is unstudied.
  • Recommended cycle: Trial protocol was 90 days continuous. Mini-pig data showed continuous > intermittent. There is no validated maintenance schedule.
  • Reset protocol if needed: N/A — no prolonged-use data exists to define one.
▸ Stacking deep dive

Synergistic with (theoretical, untested clinically)

  • finasteride / dutasteride (5α-reductase inhibitors) — DHT suppression de-represses Wnt/β-catenin in susceptible follicles; SM-04554 directly activates β-catenin downstream. Pathway-converging combo, mechanistically clean. Never tested clinically.
  • minoxidil (topical) — Mechanistically distinct (anagen prolongation + vasodilation + minor Wnt activation by minoxidil sulfate) vs primary Wnt activation. Plausible additive on different cycle phases. Never tested clinically.
  • CB-03-01 (clascoterone topical) — topical AR antagonist, mechanistically orthogonal to Wnt. Theoretically combinable in the same way minoxidil + RU58841 is combined. Never tested.
  • PP-405 (Pelage) — different next-generation "wake stem cells" thesis (mitochondrial pyruvate carrier inhibitor → glycolytic shift in follicle stem cells). Mechanistically parallel rather than convergent. No data; combo would be speculative.

Avoid stacking with

  • Other Wnt-pathway activators (lithium chloride, GSK-3 inhibitors, BIO, CHIR99021) — redundant amplification of a developmental pathway with off-target proliferation risk. Theoretical only; no documented case.
  • Topical retinoids at high concentration on the same area — vehicle/penetration interactions unstudied; if combined, separate by hours.

Neutral / safe co-administration (theoretical)

  • All the user's existing V-stack supplements (citicoline, NAC, magnesium, fish oil, PS, theanine, rhodiola, curcumin, creatine, beta-alanine, vitamin D3, glycine, vitamin C) — no mechanistic interaction with topical Wnt modulator
  • Modafinil, bromantane, BPC-157, peptides — no mechanistic conflict
  • Standard caffeine intake — fine
▸ Drug interactions deep dive
  • Systemic CYP profile: Not publicly disclosed. Topical exposure with minimal systemic absorption (Phase 1 PK suggests low plasma levels) implies low likelihood of CYP-mediated drug interactions, but not formally characterized.
  • Hormonal contraceptive interactions: Not characterized. Trials enrolled men only.
  • Topical scalp products (ketoconazole shampoo, tretinoin, ru58841, finasteride solution): No PK data, theoretical vehicle/penetration interactions only.
▸ Pharmacogenomics

No published data. Wnt-pathway component polymorphisms (LRP5/6, FZD receptors, β-catenin/CTNNB1, Axin1/2) exist and modulate Wnt signaling tone in development and disease, but no SM-04554 trial reported genotype-stratified analysis. Whether responder/non-responder split in the failed Phase 3 was driven by Wnt-pathway pharmacogenomics is unknowable from public data.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research chemical (powder) MedChemExpress (medchemexpress.com/dalosirvat.html) ~$120-300 / 5-25 mg High (CoA available) Research use only, no human-grade certification, no formulated topical
Research chemical (powder) Probechem, TargetMol, Xcess Biosciences similar pricing tier Medium-High Same caveats — academic screening compound
Research chemical (formulated topical, gray market) Umbrella Labs, NutraBiotech (occasional) ~$50-150 / topical bottle Medium-Low Vehicle composition unverified; concentration accuracy unverified; not a clinical-grade reproduction of Samumed's vehicle
Compounding pharmacy Not available — — No compounding pharmacy formulates SM-04554 — not on any FDA bulk substances list, no human-grade clinical reference for a compounder to copy
Rx pathway None — — Investigational only; never approved; Biosplice is no longer pursuing development
Clinical trial enrollment None active — — Phase 3 completed Jan 2021; no ongoing trials. Biosplice seeking out-licensing — until a successor sponsor restarts development, no trial path

Sourcing reality: A research-chem powder route exists, but reformulating it into a topical with the right vehicle, concentration, and stability is not a casual exercise. This is functionally a non-available drug for self-trial purposes — and even if reformulated correctly, you'd be replicating a drug whose Phase 3 data is so quiet the sponsor walked away.

▸ Biomarkers to track (deep)

If you trialed this (not recommended):

  • Baseline: Standardized macrophotography (Hamilton-Norwood angles), trichoscopy non-vellus density count if available, scalp photo with reference grid. Optional baseline scalp biopsy with Ki-67 / β-catenin staining (research-only).
  • During use: Photo series at month 1, 2, 3 (the trial primary endpoint window). Trichoscopy non-vellus density at same intervals.
  • Post-treatment: Photo + trichoscopy at +45 days (replicating the trial washout window) and +90 / +180 days for durability.
  • Skip: BP, HR, blood work (no systemic exposure → no relevant systemic biomarkers).
▸ Controversies / open debates Live debate

1. Phase 3 silence — what does it mean

Phase 3 (NCT03742518, n=625) completed January 2021. Five years on, no published results. In commercial pharma, this combination — large RCT completing on schedule, no peer-reviewed publication, sponsor removing asset from pipeline materials, sponsor offering the program for out-licensing — is the canonical pattern of a failed primary endpoint that the sponsor declined to publish. The trial was registered (so the obligation to report results exists under FDA Final Rule), but enforcement of timely reporting is weak and conference-abstract presentation often substitutes for full publication.

The honest 2026 read: Phase 3 either failed the primary endpoint outright, or the effect size was so small that the sponsor concluded the asset was not commercially viable. Either outcome means the Phase 2 signal didn't replicate at scale.

2. The inverted dose-response in Phase 2

The 0.15% group outperformed the 0.25% group on net hair count change. Possible explanations: (a) genuine bell-shaped dose-response — too much Wnt activation tips into off-target effects or pathway desensitization, (b) vehicle-saturation artifact at higher concentration, (c) statistical noise in a 100-per-arm trial. Samumed never publicly explained the finding. In a well-behaved drug-development program, an inverted dose-response is a red flag that triggers re-evaluation of the dose-response model — this didn't visibly happen, and 0.15% was carried forward to Phase 3 unchanged. The fact that the chosen Phase 3 dose was empirically the better one in Phase 2 but with no mechanistic explanation is itself a yellow flag.

3. Sister compound lorecivivint (SM04690) failure as platform readacross

Samumed's broader Wnt-modulation platform produced lorecivivint for knee osteoarthritis. Phase 3 results in 2022-2023 were also negative on primary cartilage and pain endpoints in the largest trial. This is two Phase 3 failures from the same Wnt-modulation platform under the same sponsor, which is a serious platform-credibility hit that extends to SM-04554 by readacross. Any successor program (whether Biosplice's or an out-licensee's) inherits this baseline skepticism.

4. Follicular neogenesis claim — independent replication

The Phase 2 biopsy paper claimed follicle counts increased and interpreted this as evidence of follicular neogenesis (de novo follicle formation in adult scalp). The hair biology community is divided on whether this is biologically possible in adult human skin — most evidence supports anagen reactivation and miniaturized-follicle re-thickening rather than true new-follicle formation. No independent histological replication of the SM-04554 neogenesis claim has been published, which would be the standard test for a finding of this importance.

5. The "wake stem cells, then withdraw" thesis as a class

Even if SM-04554 specifically failed, the broader thesis — that a finite course of a stem-cell-reactivating drug could produce durable hair regrowth without lifelong daily dosing — is appealing and is being pursued by PP-405 (Pelage Pharmaceuticals) via a completely different mechanism (mitochondrial pyruvate carrier inhibition → metabolic shift in follicle stem cells). PP-405 has a recent positive Phase 2a readout (June 2025: ~31% of treated men with higher-grade AGA showed >20% density gain at week 8 after just 4 weeks of treatment). Whether PP-405 holds up in Phase 3 will be the more important data point for the class than SM-04554's residual signal.

6. Research-chem self-trial — why it's mostly absent from the AGA community

RU58841 has a robust community self-trial culture (clear protocol, vendor verification, peer-reviewed PK basis). SM-04554 doesn't, despite similar accessibility. The reasons appear to be: (a) the Phase 3 silence killed enthusiasm at exactly the moment the community would have started bulk self-trials, (b) the Phase 2 effect size was modest enough to make an unverified-vehicle DIY topical look like a low-yield bet vs the proven canon, (c) the molecule's vehicle sensitivity (hydroalcoholic + propylene glycol formulation reportedly important for stability and penetration) is harder for community formulators to replicate than RU58841's straightforward ethanol/PG vehicle. The community's relative disinterest is itself a useful signal.

▸ Verdict change log
  • 2026-05-10 — Initial verdict: WATCH-LIST (HIGH confidence). Mechanism interesting (Wnt activation as a distinct lever from anagen prolongation and DHT suppression), Phase 2 produced a real if modest signal, but Phase 3 results undisclosed and Biosplice walked away — strongest possible negative read short of a published failed trial. For the user (no MPB at 20), this is treatment for a non-existent condition. Re-eval triggers: (1) Phase 3 results published or leaked with positive efficacy, (2) Biosplice or out-licensee restarts development with a clear path forward, (3) PP-405 (different mechanism, same "wake stem cells" thesis) succeeds in Phase 3 — would validate the class even if SM-04554 specifically is dead, (4) MPB onset in the user → revisit AGA pipeline as a class.
▸ Open questions / gaps Open
  • What did Phase 3 actually show? Public data does not exist. Without it, every other question is unanswerable.
  • What is the true upstream target of SM-04554? CLK / DYRK kinases vs other entry into the Wnt pathway is not extensively published. Matters for off-target safety and for understanding why dose-response inverted.
  • Is the Phase 2 follicular neogenesis claim biologically real or a counting artifact? No independent replication exists.
  • Does the "continued gains during washout" pattern hold beyond 135 days? No long-term human data published.
  • What is the true effect size at 6, 12, 24 months of continuous use? Unknown.
  • Is there a successor compound or out-licensee? As of May 2026, no public announcement of a third-party developer picking up SM-04554. PP-405 occupies the same conceptual space with different chemistry.

References

Lim X et al. — Distinct functions for Wnt/β-catenin in hair follicle stem cell proliferation and survival — Cell Stem Cell 2013 (PMID 24315444)

pubmed.ncbi.nlm.nih.gov · 2013

foundational hair-follicle Wnt biology

View Study

Veltri A, Lang C, Lien WH — Concise Review: Wnt Signaling Pathways in Skin Development and Epidermal Stem Cells — Stem Cells 2018 (PMID 29086457)

pubmed.ncbi.nlm.nih.gov · 2018

Wnt pathway review in hair follicle context

View Study

Yazici Y, Smith SR, Swearingen CJ, et al. — Safety and efficacy of a topical treatment (SM04554) for androgenetic alopecia (AGA): Results from a phase 1 trial — JAAD 2016

jaad.org · 2016

00674-5/abstract) — Phase 1 first-in-human safety + tolerability publication

View Source

Samumed Phase 2 — Safety and biopsy outcomes of a topical treatment (SM04554) for male androgenetic alopecia (AGA): Results from a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial — JAAD 2017

jaad.org · 2017

31355-5/abstract) — Phase 2 biopsy + follicle count publication

View Source

ClinicalTrials.gov NCT02275351

clinicaltrials.gov

Phase 1 SM04554 topical AGA

View Source

ClinicalTrials.gov NCT02503137

clinicaltrials.gov

Phase 2 biopsy SM04554 topical AGA

View Source

ClinicalTrials.gov NCT03742518

clinicaltrials.gov · 2021

Phase 2/3 SM04554 efficacy + safety, n=625, completed Jan 2021, results undisclosed

View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…